Used in the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases, this antibody targets CLEC4C (also known as BDCA-2), a receptor found on plasmacytoid dendritic cells (pDCs). By binding to CLEC4C, it inhibits the production of type I interferons, which are key drivers of autoimmune inflammation. This suppression helps reduce disease activity in lupus patients, particularly those with elevated interferon signatures. It is administered intravenously or subcutaneously in clinical settings and has shown promise in reducing skin lesions, joint symptoms, and flare rates. Ongoing studies explore its use in related conditions like lupus nephritis and cutaneous lupus.